Last reviewed · How we verify
IHL42X
At a glance
| Generic name | IHL42X |
|---|---|
| Also known as | IHL-42X |
| Sponsor | Incannex Healthcare Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (PHASE2, PHASE3)
- Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IHL42X CI brief — competitive landscape report
- IHL42X updates RSS · CI watch RSS
- Incannex Healthcare Ltd portfolio CI